By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Pharmacyclics, Inc. 

995 East Arques Avenue

Sunnyvale  California  94086  U.S.A.
Phone: 408-774-0330 Fax: 408-774-0340


Company News
Ex-Pharmacyclics (PCYC) CEO Banks $33.5 Million for Startup Corvus Pharma 7/6/2015 6:22:23 AM
Pharmacyclics (PCYC) Release: Ibrutinib (IMBRUVICA) Improved Survival For Treatment-Naive Chronic Lymphocytic Leukemia Patients In Phase III RESONATE-2 Trial 6/4/2015 7:28:29 AM
Pharmacyclics (PCYC) Release: Phase III HELIOS Study Results Show Ibrutinib (IMBRUVICA) Combination Therapy Significantly Increased Progression-Free Survival In Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients 6/1/2015 6:27:26 AM
Pharmacyclics (PCYC) Release: Analysis Of Phase III RESONATE Data Shows Adherence To The Recommended 420mg Dose Of IMBRUVICA (Ibrutinib) Results In Improved Efficacy Benefits In Patients With Chronic Lymphocytic Leukemia 6/1/2015 6:16:50 AM
Pharmacyclics (PCYC) Release: Ibrutinib (IMBRUVICA) Phase Ib/II Data Show Promise In Patients With Chronic Graft-Versus-Host-Disease 6/1/2015 6:12:15 AM
Pharmacyclics (PCYC) Release: Ibrutinib (IMBRUVICA) In Combination With Anti-PD-L1 Antibody (MEDI4736) Study Commences For Patients With Two Relapsed/Refractory Blood Cancers 5/28/2015 7:26:28 AM
AbbVie (ABBV) Completes Acquisition Of Pharmacyclics (PCYC) 5/26/2015 6:42:12 AM
AbbVie (ABBV) Announces Expiration Of Hart-Scott-Rodino Waiting Period AbbVie's Acquisition Of Pharmacyclics (PCYC) 5/22/2015 6:15:18 AM
Pharmacyclics (PCYC) Release: European Medicines Agency Issues Positive Opinion, Recommends Full Approval of IMBRUVICA (ibrutinib) To Treat Waldenstrom's Macroglobulinemia 5/22/2015 6:11:55 AM
AbbVie (ABBV) Announces Offer Consideration For Acquisition Of Pharmacyclics (PCYC) 5/21/2015 8:33:38 AM